Graft vs. Host Disease

Graft-versus-host disease (GVHD) is a serious complication that can happen after a stem cell or bone marrow transplant. It occurs when the donated immune cells (the "graft") see the recipient's body (the "host") as foreign and attack it. This immune reaction can affect various organs, leading to a range of symptoms and requiring careful management.

What is Graft vs. Host Disease?

Graft-versus-host disease (GVHD) is a serious complication that can happen after a stem cell or bone marrow transplant. It occurs when the new, donated immune cells (the "graft") see the recipient's body (the "host") as foreign and attack it. This immune system reaction can cause inflammation and damage to various organs, leading to a range of symptoms.

Graft-versus-host disease is a common and potentially life-threatening complication of allogeneic transplants. An allogeneic transplant is when you receive stem cells from a donor, rather than your own cells (autologous transplant). The goal of a stem cell transplant is to replace damaged or diseased bone marrow with healthy cells, often used to treat cancers like leukemia or lymphoma, or other blood disorders (MedlinePlus). There are two main types of GVHD: acute and chronic. Acute GVHD usually develops within the first 100 days after the transplant, though it can sometimes appear later. Chronic GVHD typically develops more than 100 days after the transplant and can last for many months or even years. Both types can range from mild to severe, affecting different parts of the body (Mayo Clinic). The underlying issue is that the donor's immune cells, specifically T-cells, are designed to identify and destroy foreign invaders. In GVHD, these cells mistakenly identify the recipient's healthy cells as foreign and launch an attack. This is why careful matching between donor and recipient is crucial, but even with a good match, GVHD can still occur (MedlinePlus, Mayo Clinic).

Symptoms

The symptoms of graft-versus-host disease (GVHD) vary depending on whether it is acute or chronic, and which organs are affected. Common signs of acute GVHD often include skin rashes, stomach upset, and liver problems. Chronic GVHD can present with a wider range of symptoms, affecting the skin, eyes, mouth, lungs, and other organs, often mimicking autoimmune diseases.

Acute GVHD most commonly affects the skin, gastrointestinal (GI) tract, and liver. Skin symptoms often appear as a rash, which can be itchy or painful, and may look like a sunburn. It typically starts on the palms of the hands, soles of the feet, ears, or shoulders and can spread across the body. GI symptoms include nausea, vomiting, diarrhea (which can be watery or bloody), and abdominal pain. Liver involvement may cause yellowing of the skin and eyes (jaundice) and abnormal liver function tests (MedlinePlus, Mayo Clinic). Chronic GVHD can affect almost any organ in the body and often has more varied and persistent symptoms. Skin changes can include dryness, thickening, tightening, or darkening, sometimes resembling scleroderma. Eye symptoms may involve dryness, irritation, and sensitivity to light. In the mouth, chronic GVHD can cause dryness, pain, sensitivity to certain foods, and mouth sores. It can also affect the lungs, leading to shortness of breath, or the joints, causing stiffness and pain (Mayo Clinic). Other potential symptoms of chronic GVHD include hair loss, brittle nails, vaginal dryness, and muscle weakness. Because chronic GVHD can affect so many different systems, its symptoms can sometimes be mistaken for other conditions. It is important to report any new or worsening symptoms to your transplant team so they can be properly evaluated (MedlinePlus).

Causes & risk factors

Graft-versus-host disease (GVHD) is caused by the donated immune cells attacking the recipient's body after an allogeneic stem cell or bone marrow transplant. Key risk factors include a mismatch between the donor and recipient's tissue types, the donor's age, and the type of conditioning treatment received before the transplant. Even with a good match, some risk remains.

The fundamental cause of GVHD is an immune system reaction. After an allogeneic transplant, the donor's T-cells, which are part of the immune system, recognize the recipient's cells as "foreign" because they have different human leukocyte antigens (HLAs). HLAs are proteins on the surface of cells that help the immune system tell the difference between the body's own cells and foreign invaders. Even a small difference in HLA types can trigger an immune response (MedlinePlus, Mayo Clinic). Several factors can increase the risk of developing GVHD. The degree of HLA mismatch between the donor and recipient is a primary risk factor; the more differences, the higher the risk. However, even with a perfect match, GVHD can still occur in some cases. The age of the donor and recipient can also play a role; older donors and recipients may have a higher risk. The source of the stem cells (bone marrow, peripheral blood, or umbilical cord blood) can also influence risk (Mayo Clinic). Other risk factors include the intensity of the conditioning regimen (chemotherapy and/or radiation) given before the transplant, which can damage the recipient's tissues and make them more susceptible to attack. The type of immunosuppressive medications given after the transplant to prevent GVHD, and how well the recipient responds to them, also affects risk. Certain infections after transplant can also increase the likelihood of GVHD (MedlinePlus, Mayo Clinic).

How it's diagnosed

Graft-versus-host disease (GVHD) is diagnosed based on your symptoms, a physical exam, and a review of your medical history following a stem cell transplant. Doctors often confirm the diagnosis by taking small tissue samples (biopsies) from affected organs like the skin, liver, or gut. These biopsies help identify the specific immune cell changes characteristic of GVHD and rule out other conditions.

Diagnosing GVHD typically begins with a thorough evaluation of your symptoms. Your transplant team will ask about any new or worsening issues, such as skin rashes, digestive problems, or changes in liver function. A physical examination will help identify visible signs, like skin discoloration or jaundice. Blood tests are also crucial to check organ function, particularly liver and kidney function, and to rule out infections (MedlinePlus, Mayo Clinic). To confirm a diagnosis of GVHD and determine its severity, doctors often perform biopsies. This involves taking a small tissue sample from an affected area, such as a skin rash, the lining of the stomach or intestine, or the liver. A pathologist then examines these samples under a microscope to look for specific cellular changes and inflammation patterns that are characteristic of GVHD (Mayo Clinic). It's important to differentiate GVHD from other post-transplant complications, such as infections or drug side effects, which can sometimes present with similar symptoms. Your medical team will consider all these possibilities. Once GVHD is diagnosed, its severity is graded, which helps guide treatment decisions. This grading system considers the extent of organ involvement and how much it impacts your daily life (MedlinePlus).

Treatment options

Treatment for graft-versus-host disease (GVHD) aims to suppress the immune response and reduce inflammation, while also managing symptoms. The primary treatment usually involves corticosteroids, such as prednisone, which help calm the attacking immune cells. If corticosteroids are not enough, other immunosuppressive drugs or targeted therapies may be used, often in combination, to control the disease.

The cornerstone of GVHD treatment, especially for moderate to severe cases, is corticosteroids. These powerful anti-inflammatory drugs work by suppressing the immune system, reducing the attack on the recipient's tissues. Corticosteroids like prednisone are often given in high doses initially, which are then slowly reduced over time as symptoms improve. However, long-term use of corticosteroids can have side effects, so doctors aim to use the lowest effective dose for the shortest possible duration (MedlinePlus, Mayo Clinic). If GVHD does not respond adequately to corticosteroids, or if the side effects are too severe, other immunosuppressive medications may be used. These include drugs like tacrolimus, cyclosporine, mycophenolate mofetil, or sirolimus. These medications work through different mechanisms to dampen the immune response. For chronic GVHD, a wider range of therapies might be considered, including extracorporeal photopheresis (ECP), which treats blood cells outside the body with UV light and a drug (Mayo Clinic). Newer targeted therapies are also emerging, particularly for chronic GVHD that is resistant to initial treatments. These include drugs like ruxolitinib, which targets specific pathways involved in inflammation. Clinical trials are continuously exploring new agents and combinations to improve outcomes for people with GVHD. The choice of treatment depends on the type and severity of GVHD, the organs affected, and your overall health (Cochrane Library, Mayo Clinic).

Recovery & outlook

The recovery and outlook for graft-versus-host disease (GVHD) vary widely depending on its type, severity, and how well it responds to treatment. Mild cases of acute GVHD often resolve completely, but severe acute GVHD can be life-threatening. Chronic GVHD can be a long-term condition, sometimes requiring ongoing treatment for months or years, and may significantly impact quality of life.

For many people, especially those with mild acute GVHD, symptoms can resolve completely with treatment. However, severe acute GVHD can be a serious and potentially fatal complication. The outlook is generally better for those whose GVHD responds quickly to initial corticosteroid therapy. Complications of acute GVHD can include severe infections due to a suppressed immune system, or organ damage (Mayo Clinic). Chronic GVHD often presents a more complex and prolonged recovery. It can affect multiple organs and may require long-term immunosuppressive therapy, which carries its own risks, such as increased susceptibility to infections and other side effects. While chronic GVHD can significantly impact a person's quality of life, many individuals learn to manage their symptoms and lead fulfilling lives. The goal of treatment is to control the disease, minimize symptoms, and reduce the need for strong immunosuppressants over time (MedlinePlus). The long-term outlook for GVHD is continuously improving with advances in transplant techniques, better donor matching, and new treatment options. Regular follow-up with your transplant team is essential to monitor for GVHD, manage its symptoms, and address any complications. Your care team will work with you to develop a personalized management plan aimed at optimizing your health and well-being (Cochrane Library, Mayo Clinic).

When to see a doctor

You should contact your transplant team or doctor immediately if you experience any new or worsening symptoms after a stem cell transplant, as these could indicate graft-versus-host disease (GVHD). Red-flag signs include a new skin rash, persistent nausea, vomiting, diarrhea, yellowing of the skin or eyes (jaundice), or unexplained fever. Early detection and treatment are crucial for managing GVHD effectively.

After a stem cell transplant, it is vital to be vigilant for any changes in your health. Your transplant team will provide specific instructions on what symptoms to watch for. Do not hesitate to contact them if you notice a new rash, especially if it's itchy or painful, or if you develop any digestive issues like severe abdominal pain, persistent nausea, vomiting, or diarrhea, particularly if it contains blood (MedlinePlus, Mayo Clinic). Other urgent signs that warrant immediate medical attention include any yellowing of your skin or the whites of your eyes (jaundice), dark urine, or unexplained fever. These symptoms could indicate liver involvement or a serious infection. Any new shortness of breath, persistent cough, or significant changes in your vision or mouth (like severe dryness or sores) should also be reported promptly (Mayo Clinic). Remember that your transplant team is your primary resource for any health concerns after your transplant. They are best equipped to evaluate your symptoms, determine if they are related to GVHD or another complication, and initiate appropriate treatment. Early intervention can often prevent GVHD from becoming more severe and improve your overall outcome (MedlinePlus).

Frequently asked questions

Can GVHD happen even if the donor and recipient are perfectly matched?

Yes, even with a perfect match of human leukocyte antigens (HLAs), graft-versus-host disease (GVHD) can still occur. While a good match significantly reduces the risk, the immune system is complex, and other minor differences between donor and recipient cells can sometimes trigger the reaction. (Mayo Clinic)

Is GVHD contagious?

No, graft-versus-host disease (GVHD) is not contagious. It is an immune reaction within the recipient's body, caused by the donated cells. You cannot catch GVHD from someone who has it, nor can you transmit it to others. (MedlinePlus)

How long does GVHD typically last?

The duration of graft-versus-host disease (GVHD) varies. Acute GVHD usually appears within the first 100 days post-transplant and can resolve within weeks or months. Chronic GVHD develops later and can persist for many months or even years, sometimes requiring long-term management. (Mayo Clinic)

Can GVHD affect children?

Yes, graft-versus-host disease (GVHD) can affect people of all ages, including children, who undergo allogeneic stem cell or bone marrow transplants. The principles of diagnosis and treatment are similar, though specific considerations for pediatric patients are taken into account. (MedlinePlus)

Are there ways to prevent GVHD?

While GVHD cannot always be entirely prevented, doctors take several steps to reduce the risk. These include careful donor matching, removing T-cells from the donor graft (T-cell depletion), and giving immunosuppressive medications to the recipient before and after the transplant. (Mayo Clinic, Cochrane Library)

What is the difference between acute and chronic GVHD?

The main difference between acute and chronic graft-versus-host disease (GVHD) is the timing of onset and the range of symptoms. Acute GVHD typically occurs within 100 days post-transplant, often affecting the skin, gut, and liver. Chronic GVHD usually develops after 100 days and can affect almost any organ, with symptoms often mimicking autoimmune conditions. (Mayo Clinic)

Sources

• MedlinePlus — Graft vs. Host Disease
• Mayo Clinic — Graft vs. Host Disease
• Cochrane Library — Graft vs. Host Disease